Two therapeutic monoclonal antibodies (8H9 and MGA271) targeting human B7-H3 have been evaluated clinically for treatment in human solid tumors including non-small cell lung cancer, triple negative breast cancer, brain and CNS tumors and sarcomas, but these trials revealed only marginal efficacy. Here, CD276 is linked to sarcoma.